We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Partners to Establish Center for Medical Cannabis R&D in Israel

By LabMedica International staff writers
Posted on 20 Mar 2016
Two Israeli-based biotechnology firms have agreed to establish a center to concentrate research, development, and commercialization of medical marihuana and other cannabis products.

The partners are iCAN- Israel Cannabis (Beit Shemesh, Israel) and Breath of Life Pharma (BOL Pharma; Israel). More...
BOL Pharma, established in 2008, is regarded as Israel’s leading medical cannabis drug development firm, while iCAN- Israel Cannabis is actively engaged in identifying and accelerating cannabis technologies in Israel.

The primary objectives of the new center will be to strengthen research and development of new cannabis-related technologies with the goal of successful commercialization. The center will serve as an incubator for cannabis innovation as well as a validator of cannabis-based medicines and agricultural-technological and topical product development based on stringent guidelines and standards.

Dr. Tamir Gedo, CEO of BOL Pharma, said, “BOL greenhouses allow developers to use the professional services and knowledge of BOL Pharma, in order to produce strains, improve growing conditions, master extraction, formulation, and production of materials under GMP conditions, and ultimately to enable companies to commercialize their research and go to market. Together with iCAN- Israel Cannabis, we will incubate companies from all over the world to test and validate medical products for the global cannabis market.”

Saul Kaye, CEO of iCAN- Israel Cannabis, said “We are thrilled to partner with BOL Pharma and provide a global incubator and proving ground for cannabis technology. We are confident our partnership will enable the most promising start-ups and innovators in Israel and abroad, to create world class products for the global cannabis economy.”

Related Links:

iCAN- Israel Cannabis
Breath of Life Pharma 



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Hematology Consumables
Bioblood Devices
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new CRISPR-based technique enables simultaneous detection of multiple pathogens in a single test (photo courtesy of Shutterstock)

CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously

Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.